June 21, 2017

Lori A. Fischbach, PhD, MPH

Associate Professor
 

Director of the Ph.D. Program in Epidemiology

Education

1997 – Ph.D. (Epidemiology), UCLA
1990 – MPH (Biostatistics) UCLA
1986 – BS (Nutritional Sciences & Dietetics), Univ of Arizona

Research Interest

Helicobacter pylori; gastric cancer; Barrett’s esophagus; meta-analysis; pressure ulcers

Current Research Projects

Retrospective Cohort Study to Evaluate the Effectiveness of Treatments for Pressure Ulcer Healing
among Nursing Home Patients (HealthPoint)

Courses Taught

  • Advanced Epidemiologic Methods
  • Advanced Epidemiology Methods Laboratory
  • Advanced Integration of Epidemiologic Concepts and Methods
  • Experimental Methods and Clinical Trials
  • Directed Research Methods

Selected Peer-reviewed Publications

  • Shewale AR, Barnes L, Fischbach L, Ounpraseuth S, Painter JP, Martin BC. Comparison of low-, moderate-, and high-molecular-weight hyaluronic acid infections in delaying time to knee surgery.  Journal of Arthroplasty. 32(10):2952-2957.e21; 2017. http://dx.doi.org/10.1016/j.arth.2017.07.007. Impact Factor: 3.055.
  • Shewale AR, Barnes L, Fischbach L, Ounpraseuth S, Painter JP, Martin BC. Comparative effectiveness of intra-articular hyaluronic acid and corticosteroid injections on time to surgical knee procedures. Journal of Arthroplasty. 32(12):3591-3597.e24; 2017. http://dx.doi.org/10.1016/j.arth.2017.07.007. Impact Factor: 3.055.
  • Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone C, Fischbach L,
  • Bazzoli F, Gisbert JP. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication (Review).  Cochrane Database of Systematic Reviews. 2016, Issue 6. Art. No.: CD009034. DOI: 10.1002/14651858.CD009034.pub2. Impact Factor: 5.939.
  • Fallone CA, Chiba N, Veldhuyzen van Zanten S, Fischbach L, Gisbert JP, Hunt R et al.
  • The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults, Gastroenterology 151(1):51-69.e14;2016. doi: 10.1053/j.gastro.2016.04.006. Impact Factor: 16.716.
  • Johnson ES, Cardarelli K, Jadhav S, Chedjieu IP, Faramawi M, Fischbach L et al. Cancer Mortality in the Meat and Delicatessen Departments of Supermarkets (1950-2006). Environment International 77:70-75;2015.  Impact Factor:  6.657.
  • Faramawi MF, Delongchamp R, Lin YS, Liu Y, Fischbach L, Abouelenien S. Environmental lead exposure is associated with visit-to-visit systolic blood pressure variability in US adults. International Archives of Occupational and Environmental Health 88(3):381-8; 2015. Impact Factor:  2.196.
  • Faramawi MF, Fischbach L, Delongchamp R, Cardenas V, Abouelenien S, Chedjieu IP, Taha N. Obesity is associated with visit-to-visit systolic blood pressure variability in the US adults.  Journal of Public Health. Dec 15; 2014. PMID 25512372 Impact Factor: 2.456.
  • Marin, Alicia C. McNicholl, Adrian G. Savarino, Vincenzo. Calvet, Xavier. Leontiadis, Grigorios I. Fischbach, Lori. Yuan, Yuhong. Gisbert, Javier P. Optimum second-line regimens for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews. 10, 2014. Accession Number 00075320-100000000-09752. Impact Factor: 6.186.
  • Fischbach L, Graham D, Kramer J, Rugge M, Verstovesek G, Parente P, et al. Association between
  • Helicobacter pylori and Barrett’s esophagus:  a case-control study. American Journal of Gastroenterology. 109(3):357-68;2014. Impact Factor: 7.553
  • Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse G, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P. Optimum duration of regimens for Helicobacter pylori eradication.  Cochrane Database of Systematic Reviews. 12:CD008337, 2013. Impact Factor: 6.186.
  • Kramer JR, Fischbach L, Richardson P, Ramsey D, Alsarraj A et al. Waist to Hip Ratio but Not Body
  • Mass Index is Associated with Increased Risk of Barrett’s Esophagus in Caucasian Men. Clinical Gastroenterology and Hepatology. 11:373-81;2013. Impact Factor: 6.648
  • Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone C, Fischbach L, Bazzoli F, Gisbert JP. Sequential versus standard triple therapy for Helicobacter pylori eradication [Protocol] \ Cochrane Database of Systematic Reviews. 3, 2013.  Impact Factor: 6.186.
  • Fischbach LA, Nordenstedt H, Kramer JR, Gandhi S, Dick-Onuoha S, Lewis A, El Serag HB. The association between Barrett’s Esophagus and Helicobacter pylori infection:  A meta-analysis. Helicobacter. 17:163-75;2012. NLM. NIHMS343105. Impact Factor: 3.109.
  • Graham DY, Fischbach LA. Empiric therapy of Helicobacter pylori infections. Canadian Medical Association Journal. 183:E506-8;2011. Impact Factor: 9.020.
  • Prieto-Jimenez CA, Cardenas V, Fischbach LA, Mulla Z, Rivera J, Dominguez D, Graham DY, Ortiz M. Double-blind randomized trial of quadruple sequential H. pylori eradication therapy in asymptomatic,  infected children in El Paso, Texas. Journal of Pediatric Gastroenterology and Nutrition. 52:319-25;2011. Impact Factor: 2.183.
  • Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infection. Nature Reviews Gastroenterology and Hepatology. 8:79-88;2011. Impact Factor: 6.186.
  • Yuan Y, Ford AC, Khan K, Forman D, Oderda G, Calvet X, Leontiadis GI, Fallone C, Gisbert JP, Fischbach L, Bazzoli F, Moayyedi P. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews. [Protocol] Issue 1;2010. Impact Factor: 6.186.
  • Cervantes D, Fischbach LA, Goodman KJ, Phillips C, Chen S, Broussard C. Exposure Helicobacter pylori-positive siblings and persistence of Helicobacter pylori infection in early childhood. Journal of Pedatric Gastroenterology and Nutrition. 50(5):481-5;2010.  Impact Factor: 2.183.
  • Graham DYY, Fischbach L. Helicobacter pylori therapy in the era of increasing antibiotic resistance eradication. Gut. 59:1143-53;2010. Impact factor: 9.766.
  • Ojha RP, Fischbach LA, Zhou Y Thertulien R. Acute myeloid leukemia following external beam radiation therapy for localized prostate adenocarcinoma: A population-based cohort study. Cancer Epidemiology. 34(3):274-8;2010. Impact factor: 1.182.
  • Broussard CS, Goodman KJ, Nurgalieva ZZ, Fischbach LA, Gold BD. Exposure to antibiotics in a United States-Mexico border birth cohort. Pediatrics 125(6):e1468-74, 2010. Impact factor: 4.687.
  • Forman, David. Bazzoli, Franco. Bennett, Cathy. Broutet, Nathalie. Chiba, Naoki. Deeks, Jonathan J.
  • Fallone, Carlo. Fischbach, Lori. Hunt, Richard. Lahaie, Raymond. Laheij, Robert. Megraud, Francis. Moayyedi, Paul. Oderda, Giuseppina. Palli, Domenico. Savarino, Vincenzo. Misiewicz, (JJ) George. Unge, Peter. Gisbert, Javier P. Kuipers, Ernst J. Calvet, Xavier. Harris, Adam. Huang, J Q. Therapies for the eradication of Helicobacter pylori. Cochrane Database of Systematic Reviews. 4, 2009. Impact Factor: 6.186.
  • Broussard CS, Goodman KJ, Phillips CV, Smith MA, Fischbach LA, Day RS, Aragaki CC.  Antibiotics taken for other illnesses and spontaneous clearance of Helicobacter pylori infection in children. Pharmacoepidemiology Drug Safety 18(8):722-9;2009. Impact factor: 2.52
  • Fischbach LA,  Bravo LE, Zarama Rosero G, Bravo JC, Ojha RP, Priest EL, Collazos T, Casabon AL, Guerrero Zambrano L, Singh KP, Correa P. A randomized clinical trial to determine the efficacy of regimens containing clarithromycin, metronidazole, and amoxicillin among histological subgroups for Helicobacter pylori eradication in a developing country. Helicobacter 14:100-108;2009. Impact factor:  2.47
  • Nurgalieva Z, Goodman KJ, Phillips CV, Fischbach L, de la Rosa M, Gold BD.  Correspondence between Helicobacter pylori antibodies and urea breath test results in a US-Mexico birth cohort. Pediatric Perinatal Epidemiology. 22:302-312;2008Impact factor: 1.83
  • Ojha RP, Thertulien R, Fischbach LA. Racial under-representation in clinical trials: Consequence, myth, and proposition. Epidemiologic Focus 1(1):e2;2008.
  • Jain MK, Aragaki C, Fischbach L, Gibson S, Arora R, May L, Vardhineni K, Lee WM.  Hepatitis C is associated with Type 2 diabetes mellitus in HIV-infected persons without traditional risk factors. HIV Medicine. 8(8):491-7;2007. Impact factor: 2.67
  • Fischbach LA, Evans E.  Meta-Analysis: The effect of antibiotic resistance status on the efficacy of triple and quadruple. First-line therapies for Helicobacter pylori. Alimentary Pharmacology and Therapeutics 26:343357;2007. Impact factor: 3.71
  • Khurana R, Fischbach L, Chiba N, Veldhuyzen van Zanten S, Sherman PM, George BA, Goodman
  • KJ, Gold BD. Meta-Analysis of Helicobacter pylori treatment efficacy in children.  Alimentary Pharmacology and Therapeutics. 25(5):523-36;2007. Impact factor: 3.71
  • Long ZB, Oeffinger KC, Fischbach LA, Harris TR, Brooks SL, Eschelman DA, Tomlinson GA, Buchanan GR. Incidence and clinical relevance of abnormal complete blood counts in long-term survivors of childhood cancer. Cancer. 106(7):1634-40;2006. Impact factor: 4.58.
  • Bourke B, Ceponis P, Chiba N, Czinn S, Ferraro R, Fischbach LA, Gold B, Hyunh H, Jacobson K,
  • Jones NL, Koletzko S, Lebel S, Moayyedi P , Ridell R, Sherman P, Veldhuyzen van Zanten S , Beck I,
  • Best L, Boland M, Bursey F, Chaun H, Cooper G, Craig B, Creuzenet C, Critch J, Govender K, Hassall
  • E, Kaplan A, Keelan M, Noad G, Robertson M, Smith L, Stein M, Taylor D, Walters T, Persaud R, Whitaker S, Woodland R.  Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents–an evidence-based evaluation. Canadian Journal of Gastroenterology 19(7):399-408;2005. Impact factor: 2.03
  • Khurana R, Fischbach L, Chiba N, Veldhuyzen van Zanten S. A current update on anti-Helicobacter pylori treatment in children. Canadian Journal of Gastroenterology 19(7):441-445;2005. Impact factor: 2.03
  • Valente L, Caughy M, Fischbach L. A self-administered questionnaire to identify diabetics at increased risk for foot ulceration or amputation: A validation study. Diabetes Educator 30(6)932944;2004. Impact factor: 1.10
  • Fischbach LA, Velhhuyzen Van Zanten S, Dickason J. Efficacy, adverse events and adherence related to first-line anti-Helicobacter pylori quadruple therapies: A meta-analysis.  Alimentary Pharmacology and Therapeutics 20:1-12;2004. Impact factor from 2002-2006: 7.06
  • Hunt R, Fallone C, Veldhuyzan van Zanten S, Canadian Helicobacter Study Group. Consensus
  • Conference: Update on the management of Helicobacter pylori:  An evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for Helicobacter pylori. Canadian Journal lof Gastroenterology 18:547-554;2004. Impact factor: 2.03
  • Fischbach LA, Correa P, Feldman M, Fontham E, Priest EL, Goodman KJ, Jain R. Increased reflux symptoms after calcium carbonate supplementation and successful Helicobacter pylori treatment:  Results from a randomized clinical trial in a population with a high prevalence of multifocal atrophic gastritis. Digestive Disease and Sciences 48(8):1487-94;2003. Impact factor: 1.87
  • Nash C, Fischbach L, Veldhuyzen Van Zanten S.  What are the global response rates to Helicobacter pylori eradication therapy? Canadian Journal of Gastroenterology Suppl B:25B-29B;2003. Impact factor: 2.03
  • Duffield-Lillico AJ, Reid ME, Turnbull BW, Slate EH, Fischbach L, Combs GF, Clark LC, Marshall J.  Baseline characteristics and the effect of selenium supplementation on cancer risk in a randomized clinical trial:  a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiology Biomarkers and Prevention 11:630-9;2002. Impact factor: 3.57 (The 14th most cited article from Cancer Epidemiology, Biomarkers and Prevention in 2002)
  • Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. International Journal of Epidemiology 31(1):128-39;2002. Impact factor: 1.97
  • Fischbach LA, Correa P, Ramirez H, Realpe J, Zarama G, Collazo T, Ruiz B, Schmidt B. Antiinflammatory and tissue-protectant drug effects: Results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer. Alimentary Pharmacology and Therapeutics 15:831-41;2001. Impact factor: 7.06
  • Spechler S, Fischbach L, Feldman M. Clinical Aspects of Genetic variability in Helicobacter pyloriJAMA 283(10):1264-66;2000. Impact factor: 23.18
  • Forman D, Bazzoli F, Bennett C, Broutet N, Chiba N, Deeks JJ, Fallone C, Fischbach L, Hunt R,
  • Lahaie R, Laheij R, Megraud F, Moayyedi P, Oderda G, Palli D, Savarino V, Misiewicz G, Unge P, Gisbert JP, Kuipers EJ, Calvet X, Harris A, Huang JQ. Therapies for the eradication of Helicobacter pylori [Protocol]. Cochrane Database of Systematic Reviews Issue 3. Art. No.: CD002298;2000. Impact Factor: 6.186.
  • Schecter A, Dai LC, Fischbach L, Päpke O. Vietnamese Dioxin Blood and Milk Levels 1970-1999 and Implications for Future Epidemiological Studies. Organohalogen Compounds (44):417-23;1999.
  • Fischbach L, Lee D, Engelhardt R, Wheeler N. The prevalence of ocular disorders found among
  • Hispanic and Caucasian children screened by the Mobile Eye Clinic. Journal of Community Health 18(4):201-11;1993. Impact factor: 1.21.
  • Book Chapters:
  • Fischbach L, Martin B. Cohort and Case Control Studies.  In:  Aparasu RR, Bentley JP, Eds, Principles of Research Design and Drug Literature Evaluation, 1st Edition:  Jones & Bartlett Learning, MA:  Burlington, 2015.
  • Van Zanten S., Fischbach LH. pylori treatment effectiveness worldwide. In: Hunt RH, Tytgat GNT eds.  Helicobacter pylori:  Basic Mechanisms to Clinical Cure 2003. Dordrecht: Kluwer Academic Publishers, 2003.

Selected Presentations

  • 2018     Training cosmetology students in Arkansas to help dermatologists prevent skin cancer and detect melanomas earlier.  Arkansas Department of Health, Grand Rounds. February 15.
  • 2017     Keynote Presentation. Cancer Prevention in Nariño, Colombia. 1st Annual Departmental Cancer Prevention Convention in Nariño, Colombia, October 5th (In Spanish).
  • 2016     Training cosmetology students in Arkansas to help dermatologists prevent skin cancer and detect melanomas earlier.  Arkansas Cosmetology Board.  September 19.
  • 2016     Educational Intervention for Skin Cancer Prevention in Cosmetology Students.  Arkansas Cancer Coalition Quarterly Meeting. Cancer Arkansas Radiation Therapy Institute, Little Rock, AR.  February 2.
  • 2016     Should corpus-predominant gastritis be used to identify H pylori positive patients at high risk for progression in the gastric precancerous process?  COPH Special Seminar.
  • 2015     Treatment of Helicobacter pylori. Public Health Seminar
  • 2015     The Best Helicobacter pylori Treatment for Countries with the Heaviest Burden of Infection: Results from a Meta-analysis of Studies from 43 Countries Worldwide.1st Annual World Congress of Digestive Diseases. December 17th in Nanjing, China.
  • 2015     Helicobacter pylori Treatment for Countries with the Heaviest Burden of Infection: Preliminary results from a meta-analysis of studies from developing countries. CDC China. December 16th in Nanjing, China.
  • 2015     The Effect of Higher Doses for Proton Pump Inhibitors for Rescue Therapies. Presentation for the North American Clinical Practice Guidelines for Helicobacter pylori Treatment. June 13th at the Toronto Consensus Meeting in Toronto, Canada.
  • 2015     Optimal Duration of Traditional Bismuth Quadruple Therapy as a Rescue Therapy. Presentation for the North American Clinical Practice Guidelines for Helicobacter pylori Treatment.  June 12th at the Toronto Consensus Meeting in Toronto, Canada.